Antimicrobial Resistance
Vancomycin-resistant infections are low among liver transplant candidates
Published in Hepatitis Weekly, September 1st, 2003
"The orthotopic liver transplant (OLT) population has been particularly affected by the increase in vancomycin-resistant enterococcus (VRE) infections in recent years. Pretransplant colonization prevalence, the role of spontaneous bacterial peritonitis (SBP) antimicrobial prophylaxis as a risk factor, and the risk of post-OLT infection in colonized patients are all unknowns. We prospectively evaluated OLT candidates at our center with the aim of answering these questions," investigators in the United States reported.
"Vancomycin-resistant enterococcus colonization status was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-09-01)
More Articles from Hepatitis Weekly
- Immunology
Chromatin antibodies associate with autoimmune hepatitis pathology - Immunology
Inactivated parapoxvirus ovis protects against hepatitis and herpes viruses - HIV/AIDS Coinfection
SPECT imaging may replace liver biopsies in HIV/HCV coinfected patients - Liver Failure
Hybrid artificial liver support systems can stem hepatic decline - Viral Hepatitis
GBV-B infections in marmosets closely resemble human hepatitis C virology - Antiviral Therapy
Several factors contribute to treatment failure in chronic hepatitis C - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
